
Sweden-based KDventures AB (Nasdaq Stockholm: KDV) today announced that its portfolio company PharmNovo has completed a capital raise of approximately 39 million kronor ($4.1 million), with participation from external investors.
The capital raise forms part of the financing round intended to enable the company's planned Phase II study of its drug candidate PN6047. In connection with the transaction, KDventures' book value of its holding in PharmNovo has been written down to 5 million kronor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze